United Therapeutics Corporation (UTHR)vsViatris Inc (VTRS)
UTHR
United Therapeutics Corporation
$562.02
-0.65%
HEALTHCARE · Cap: $25.15B
VTRS
Viatris Inc
$19.91
+4.96%
HEALTHCARE · Cap: $21.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 367% more annual revenue ($14.74B vs $3.15B). UTHR leads profitability with a 41.6% profit margin vs -2.8%. UTHR appears more attractively valued with a PEG of 2.22. UTHR earns a higher WallStSmart Score of 61/100 (C+).
UTHR
Buy61
out of 100
Grade: C+
VTRS
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.7%
Fair Value
$479.26
Current Price
$562.02
$82.76 discount
Margin of Safety
-81.6%
Fair Value
$8.88
Current Price
$19.91
$11.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Revenue declined 1.9%
4.9% revenue growth
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
UTHR profiles as a declining stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.86 — expect wider price swings.
VTRS is growing revenue faster at 4.9% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 42/100), backed by strong 41.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?